Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Correlated Hypokalaemia-Reference-Cited by-同舟云学术

Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Correlated Hypokalaemia

Published:2019-12-05 Issue:1 Volume:8 Page:161-169
ISSN:2366-1070
Container-title:Oncology and Therapy
language:en
Short-container-title:Oncol Ther

Author:

Giampieri Riccardo^ORCID,Maccaroni Elena,Sotte Valeria,Baleani Maria G.,Meletani Tania,Giglio Enrica,Pecci Federica,Bittoni Alessandro,Lanese Andrea,Cantini Luca,Mentrasti Giulia,Lucarelli Alessandra,Berardi Rossana

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s40487-019-00102-3.pdf

Reference27 articles.

1. Schwartzberg LS, Rivera F, Karthaus M, et al. A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014;32(21):2240–7.

2. Douillard JY, Siena S, Cassidy J, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol. 2014;25(7):1346–55. https://doi.org/10.1093/annonc/mdu141. Epub 2014 Apr 8.

3. Stein A, Atanackovic D, Hildebrandt B, et al. Upfront FOLFOXIRI + bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer. Br J Cancer. 2015;113(6):872–7. https://doi.org/10.1038/bjc.2015.299. Epub 2015 Sep 3.

4. Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16(13):1306–15. https://doi.org/10.1016/S1470-2045(15)00122-9. Epub 2015 Aug 31.

5. Cunningham D, Starling N, Rao S, et al. Upper gastrointestinal clinical studies group of the national cancer research institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36–46. https://doi.org/10.1056/NEJMoa073149.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Capecitabine/glucose/oxaliplatin;Reactions Weekly;2020-06